On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

Alexion bets up to $265M on Blueprint's precision medicine platform

Rare disease magnate Alexion is aligning itself with biotech Blueprint Medicines, borrowing the company's development technology to spotlight new treatments for genetic disorders.

Blueprint Medicines Announces Strategic Collaboration with Alexion to Advance Kinase Drug Candidates in Rare Genetic Disease

CAMBRIDGE, Mass., March 3, 2015 -- Blueprint Medicines today announced a strategic collaboration with Alexion to discover, develop and commercialize novel drug candidates for an undisclosed...

AtheroNova files for Ch.11 bankruptcy protection; Oncolytics nabs orphan drug designation;

@FierceBiotech: Bullish ex-Elan chief plots a $43M buy-in for upstart Serenus. Article | Follow @FierceBiotech @JohnCFierce: Remember when the NVCA wailed over the unsustainable VC model in biotech,...

Valeant starts carving up what remains of Dendreon, axing 77 staffers

Valeant has wasted no time in getting down to brass tacks at its newly acquired subsidiary Dendreon. The company notified the state of Washington that it is laying off 77 staffers from the biotech's steadily shrinking roster of employees, according to a report from the Seattle Times.

Merck touts a bright future in biosimilars with a stable of would-be blockbusters

Merck may trail the first movers in the coming onslaught of blockbuster biosimilars, but the pharma giant is heralding a crop of late-stage copycat treatments it believes can snag a share of the soon-to-boom market.

Ambitious cancer R&D plans may explain Merck KGaA cutbacks

Anyone looking for some perspective on Merck KGaA's recent R&D cutbacks should check out an interview CFO Marcus Kuhnert gave to CNBC. 

Serenus Biotherapeutics Enters Equity Purchase and Acquisition Agreement With Ireland-Based Global Life Sciences Company

Malin Corporation plc to Invest up to $43 Million for up to a 76 Percent Stake in Specialty Pharmaceutical Focused on Africa SAN FRANCISCO, CA and JOHANNESBURG, SOUTH AFRICA--(Marketwired - Mar 3,...

Bullish ex-Elan chief plots a $43M buy-in for upstart Serenus

Fresh from floating plans to raise up to $364 million in an IPO for his life sciences fund, ex-Elan chief Kelly Martin is going into the biopharma business with his former chief medical officer, Menghis Bairu. Martin announced today that he's sinking up to $43 million into Bairu's newborn Serenus Biotherapeutics with plans to gain a majority interest in the company.

Boehringer takes pole position with its 'breakthrough' anti-anticoagulant

Boehringer Ingelheim submitted U.S., European and Canadian applications for an antidote to its own Pradaxa, leading the way among companies developing treatments that reverse the effects of blockbuster next-generation anticoagulants.